[Federal Register Volume 83, Number 129 (Thursday, July 5, 2018)]
[Notices]
[Page 31382]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-14400]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Air Force

[ARH-180613D-PL]


Notice of Intent To Grant an Exclusive Patent License

    Authority:  35 U.S.C. 209; 37 CFR 404.

AGENCY: Department of the Air Force, Department of Defense.

ACTION: Notice of Intent

-----------------------------------------------------------------------

SUMMARY: Pursuant to the Bayh-Dole Act and implementing regulations, 
the Department of the Air Force hereby gives notice of its intent to 
grant an exclusive patent license agreement to Elke Therapeutics, Inc., 
a domestic business corporation of the State of New York, having a 
place of business at 105 E 34th Street, Unit 198, New York, New York 
10016.

DATES: Written objections must be filed no later than fifteen (15) 
calendar days after the date of publication of this Notice.

ADDRESSES: Submit written objections to the Air Force Materiel Command 
Law Office, AFMCLO/JAZ, 2240 B Street, Room 260, Wright-Patterson AFB, 
OH 45433-7109; Facsimile: (937) 255-3733; or Email: 
[email protected]. Include Docket No. ARH-180613D-PL in the 
subject line of the message.

FOR FURTHER INFORMATION CONTACT: Air Force Materiel Command Law Office, 
AFMCLO/JAZ, 2240 B Street, Rm 260, Wright-Patterson AFB, OH 45433-7109; 
Facsimile: (937) 255-3733; Email: [email protected].

SUPPLEMENTARY INFORMATION: The Department of the Air Force intends to 
grant the exclusive patent license agreement for the invention 
described in:

--U.S. Patent No. 8,575,069, entitled, ``HUMAN PERFORMANCE BIOMARKER 
BINDING PEPTIDES FOR NEUROPEPTIDE Y AND METHODS OF USING THE SAME,'' 
filed 15 January 2013, and issued 5 November 2013.

    The Department of the Air Force may grant the prospective license 
unless a timely objection is received that sufficiently shows the grant 
of the license would be inconsistent with the Bayh-Dole Act or 
implementing regulations. A competing application for a patent license 
agreement, completed in compliance with 37 CFR 404.8 and received by 
the Air Force within the period for timely objections, will be treated 
as an objection and may be considered as an alternative to the proposed 
license.

Henry Williams,
Acting Air Force Federal Register Liaison Officer.
[FR Doc. 2018-14400 Filed 7-3-18; 8:45 am]
 BILLING CODE 5001-10-P